Beckman Coulter Acquires Siemens Healthcare Diagnostics’ Clinical Microbiology Business
By LabMedica International staff writers Posted on 24 Jul 2014 |
Beckman Coulter (Brea, CA, USA), an indirect wholly-owned subsidiary of Danaher Corp. (Washington DC, MD, USA) has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics (Chicago, IL, USA). The transaction is expected to close in the first quarter of 2015. The agreement is subject to applicable regulatory approvals and other customary closing conditions.
The Siemens clinical microbiology business is a leader in microbial identification and antibiotic sensitivity testing (ID/AST). The business operates with a base of over 6,000 instruments globally. The microbiology product line includes the MicroScanInstruments and MicroScan panels/consumables, along with data management solutions. The MicroScan systems are known for accuracy and detection of emerging resistance.
Beckman Coulter diagnostics president Arndt Kaldowski said, "The clinical microbiology business will be an excellent complement to Beckman Coulter's Diagnostics business with a strong reputation and market position. Adding its ID/AST solutions to our existing products and services will create an opportunity to enhance our offerings to laboratory customers and improve patient care. The acquisition expands our product portfolio with differentiated analytical systems and menu that elevate our clinical capabilities for customers, while driving continued growth."
Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. The company is dedicated to providing solutions to laboratories of all sizes––offering a broad portfolio of chemistry, immunoassay, hematology, urinalysis, automation, and information systems. For further information about the company see www.beckman-coulter.com.
Related Links:
Beckman Coulter
Danaher Corp.
Siemens Healthcare Diagnostics
The Siemens clinical microbiology business is a leader in microbial identification and antibiotic sensitivity testing (ID/AST). The business operates with a base of over 6,000 instruments globally. The microbiology product line includes the MicroScanInstruments and MicroScan panels/consumables, along with data management solutions. The MicroScan systems are known for accuracy and detection of emerging resistance.
Beckman Coulter diagnostics president Arndt Kaldowski said, "The clinical microbiology business will be an excellent complement to Beckman Coulter's Diagnostics business with a strong reputation and market position. Adding its ID/AST solutions to our existing products and services will create an opportunity to enhance our offerings to laboratory customers and improve patient care. The acquisition expands our product portfolio with differentiated analytical systems and menu that elevate our clinical capabilities for customers, while driving continued growth."
Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. The company is dedicated to providing solutions to laboratories of all sizes––offering a broad portfolio of chemistry, immunoassay, hematology, urinalysis, automation, and information systems. For further information about the company see www.beckman-coulter.com.
Related Links:
Beckman Coulter
Danaher Corp.
Siemens Healthcare Diagnostics
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus